Glycosides-based Glycomedicine Development

Glycosides-based Glycomedicine Development

CD BioGlyco has abundant experience in carbohydrate-based glycomedicine development services. We expect to become customers' research assistants in the field of glycobiology and glycochemistry.

An Introduction to Glycosides

Glycosides can be defined as the compounds in which one or more sugars are combined with nonsugar molecules through glycosidic linkage. They are composed of two bound portions, a sugar moiety, named glycone, and a second portion known as the aglycone or genin. The aglycone is bound to the anomeric carbon (C-1 carbon) of the glycone. The breakdown of glycosidic linkages can be achieved by enzymes (such as β-glucosidases) or acids. The synthesis of glycosides by plants is based on the modification of secondary metabolites by glycosyltransferases, and some glycosides require additional reactions, including oxidation, acylation, and degradation. Several glycosides have therapeutic uses, with others known to possess pharmacological activities with remarkable therapeutic potential. The pharmacological activities include analgesic, anti-inflammatory, cardiotonic, antibacterial, antifungal, antiviral, and anticancer effects. Notably, the pharmacological properties of glycosides are related to their chemical structure. The aglycone portion usually determines the pharmacological action, while the glycone moiety determines the magnitude of water solubility and interferes with pharmacokinetics.

Many biologically active compounds are glycosides. Glycosides comprise several important classes of compounds such as antibiotics, hormones, sweeteners, alkaloids, flavonoids, etc. Owing to recent developments in molecular glycobiology a greater understanding has been gained of aglycon activity and – based on these findings – it has become possible to develop new, more active or more effective glycodrugs.

The representative first-, second- and third-generation macrolide glycoside antibiotics.Fig.1 The representative first-, second- and third-generation macrolide glycoside antibiotics. (Cao, et al., 2022)

Glycosides-based Glycomedicine Development Services

CD BioGlyco has developed a highly specialized carbohydrate-based glycomedicine development platform and various systematic solutions for the development or synthesis of glycosides-based glycomedicine. CD BioGlyco provides determination services of glycosides-based glycomedicine activity. We offer services for the development of aminoglycoside antibiotics for antibacterial and antiparasitic. In addition, chemical synthesis services of natural glycosides and their artificial analogs, such as steroid glycosides, triterpene glycosides, flavonoids, and phenolic glycosides are available.

Advantages of Us

  • Effective development strategies.
  • Advanced facilities and well-trained researchers.
  • Efficient method for the measurement of activity.

CD BioGlyco has comprehensive glycomedicine development platforms to help with customers' in-depth study of glycosides-based glycomedicine development. Our professional research teams provide customers with high-quality glycomedicine development services according to their needs. If you are interested in our services, please contact us to obtain more information.


  1. Cao, Xin.; et al. Carbohydrate-based drugs launched during 2000−2021. Acta Pharmaceutica Sinica B. 2022.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.